Here’s what’s in store for you in today’s issue:
🍄 Combining psilocybin with antidepressants
🍄 Vaping mushrooms?
🍄 The cure for constant hunger
🍄 Government-funded shroom trip
🍄 And more.
You’ll want to stay till the end to learn how someone gained a new skill during their first trip!
(Did a good friend forward this to you? If so be sure to subscribe here)
In this episode we have Lenny Kerman, a strategic financial consultant who works with various psilocybin and cannabis companies. He talks about how he’s invested in the space and has some valuable information for those looking to invest as well.
A new study found that combining SSRIs and psilocybin is not only safe, but may be beneficial!
Yesterday, MindMed (MNDM) announced the findings from an ongoing study conducted in collaboration with UHB Liechti Lab.
Psilocybin was found to be safe to administer with an SSRI antidepressant and did not reduce the psychedelic experience. Two weeks prior to the psilocybin dose, volunteers were give a daily pretreatment of the SSRI escitalopram. As a result, the volunteers experienced reduced anxiety and blood pressure increases that can occur with psilocybin administration.
Can shrooms treat this rare genetic disorder?
Tryp Therapeutics (TRYP) is preparing for a Phase 2a study on overeating disorders including a rare condition called Prader-Willi Syndrome, a genetic disorder that causes intellectual disability, shortness in height, and constant hunger than often leads to obesity and diabetes.
The clinical trial is expected to begin in Q4 of this year and will investigate various other eating disorders such as binge eating and hypothalamic obesity. Ten patients will be given two doses of psilocybin, which in theory will increase neuroplasticity to create healthier neural patterns related to eating habits.
The San Diego company just filed an Investigational New Drug (IND) application with the FDA, for TRP-8802, the psilocybin formulation that will be used in the study.
Mydecine (MYCO) filed a patent for a new anxiety and PTSD drug that provides more immediate relief than pure psilocybin.
The compound, MYCO-003, combines a serotonin agonist with a serotonin releasing agent – two drug classes that increase one’s sense of well-being, safety, and happiness. The formulation has shown positive preclinical data and has potential to relieve extreme anxiety before needing to provide extensive supportive care.
The patent was filed with both the United States Patent and Trademark Office (USPTO) and the World Intellectual Property Organization (WIPO).
Mydecine (MYCO) filed a patent for a new anxiety and PTSD drug that provides more immediate relief than pure psilocybin.
The compound, MYCO-003, combines a serotonin agonist with a serotonin releasing agent – two drug classes that increase one’s sense of well-being, safety, and happiness. The formulation has shown positive preclinical data and has potential to relieve extreme anxiety before needing to provide extensive supportive care.
The patent was filed with both the United States Patent and Trademark Office (USPTO) and the World Intellectual Property Organization (WIPO).
After half a century, the US federal government has started funding psychedelic research again!
A researcher at Johns Hopkins University received a U01 grant from the National Institute on Drug Abuse (NIDA) to fund a multi-site study on psilocybin for tobacco addiction, which will take place at Johns Hopkins, New York University, and the University of Alabama at Birmingham.
The researcher, Dr. Matthew W. Johnson, noted that this is the first time a psychedelic study has received funding since the War on Drugs was declared in the 70s, marking a “new era in legitimacy of psychedelic science”.
Yesterday, Wake Network Inc. received a Certificate of Drug Registration from the Jamaican Ministry of Health & Wellness for PSIL428, its microdose formulation made from natural psilocybin.
The certification allows the company to run clinical trials on anxiety and depression and makes PSIL429 available to clinics and academic institutions across the globe. Any country with a special access program can request to import the legal formulation for patient use.
In other microdosing news, MindBio Therapeutics, a subsidiary of Blackhawk Growth Corp. (BLR), is partnering with Trip Pharma’s LeichtMind clinic to launch microdosing clinical trials in Canada!
Will psychedelic therapy soon involve vaping shrooms?
Delic (DELC) is the first company to receive Health Canada approval to research psilocybin vaporization.
On Monday, Delic entered into an agreement to acquire Ketamine Wellness Clinics, a company that runs 10 ketamine infusion centers across 8 states. The deal increases Delic’s total number of clinics to 12 and adds over 60 medical professionals to the team, making it the largest psychedelic wellness chain in the US. Within the next 18 months, the company hopes to grow this number to 27 clinics!
Once granted FDA-approval, DELIC aims to offer other psychedelic treatments at these locations including MDMA and psilocybin therapy, which could potentially use the vaporization technology!
MINDCURE’s (MCUR) digital therapeutics platform could improve the psychedelic healing journey for both patients and clinicians!
The software application, iSTRYM, provides clinicians with a global database of therapy protocols, integration plans, and AI-driven data insights into patient journeys. The application connects to mobile and wearable devices to measure patients’ biological response to the treatment, allowing clinicians to provide personalized care. iSTRYM also offers a Mindfulness Suite that patients can use to explore practices like breathwork and meditation to support their healing.
This week, MINDCURE signed into an exclusive licensing agreement with ATMA Journey Centers, a private psychedelic therapy clinic in Calgary, which will grant MINDCURE access to anonymous patient data gathered from ATMA’s use of the platform.
You may want to postpone your trip to Italy till next year 😉
Italian activists collected 500,000 signatures in favour of a referendum to decriminalize marijuana and psilocybin – enough to qualify for a ballot measure!
The referendum would remove Italy’s prohibition on cultivating psychoactive substances, but the further processing required to produce most narcotics would remain illegal. Fortunately, magic mushrooms are ready to enjoy after cultivation alone!
A vote is expected to take place in spring of 2022 given that the Court of Cassation and the Constitutional Court sign off on the measure after reviewing the petition.
Back in May, UK Prime Minister Boris Johnson approved the rescheduling of psilocybin to make it easier to research its therapeutic effects.
Months have passed, yet the Home Office has failed to act, “perpetuating what can be considered the worst research blackout in scientific history,” according to the Conservative Drug Policy Reform Group (CDPRG). Crispin Blunt MP, chairman of the CDPRG, is urging the Home Office to take action fast to tackle the mental health crisis.
A Home Office spokesperson said that there are currently no plans to reschedule psilocybin due to the Misuse of Drugs Regulations 2001, but they will consider any recommendations from The Advisory Council on the Misuse of Drugs (ACMD), which is reviewing the barriers to researching controlled drugs.
This Reddit user gained a new ability during their first trip.
“I’m in my 40s and have been tone deaf as well as having hearing loss my whole life. I can’t carry a tune or recognize notes/melodies, and have never connected emotionally to music. When I dance, I’m just imitating others. I don’t know how to dance to music.
I tried magic mushrooms for the first time. My friend had music playing and at one point during my trip, I started humming and singing. I became the song and my body knew how to dance and play an instrument. My fingers were making the most intricate, precise movements- strumming an instrument like a professional musician. Dance movements came to me and I could feel it in my nervous system as I danced. Afterwards, I was still ready to believe that I was probably horribly out of tune and stumbling around and making stuff up, but my friend- who was not tripping- confirmed that I was carrying a tune, humming the song that was playing, and danced as if I had been trained and done it all my life.
This is just… unbelievable. And also merely a facet of the whole trip! I’d love to hear if this resonates with others and if there have been similar experiences!”
